Select Page

Technology Portfolio

To advance our understanding of biological processes and accelerate the discovery of new therapeutics, there is a need for advanced, high-performance technologies for high-throughput functional analysis. Cellecta focuses on the development of effective, advanced high-throughput screening technologies. Using lentiviral-based cloning and advanced library construction techniques, Cellecta has developed platforms for RNAi and CRISPR genome-wide genetic knockdown/knockout, activation and inhibition screening and a biomarker discovery technology portfolio. The following pages review some of our core technologies and capabilities.